title: Elotuzumab May Slow Multiple Myeloma.
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D000071176:Signaling Lymphocytic Activation Molecule Family; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011971:Receptors, Immunologic; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab